- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00630955
Family History Study of Alcohol Consumption Using Memantine
March 5, 2020 updated by: Yale University
NMDA Antagonist Efficacy in Reducing Human Alcohol Consumption: Impact of Family History
The purpose of this study is to evaluate the effects of the study medication, memantine (placebo, 20 mg or 40 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period.
We hypothesize that memantine will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.
We will also evaluate the influence of family history of alcoholism on the efficacy of memantine in reducing alcohol drinking behavior.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
111
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- CMHC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 21-50
- Able to read English at 6th grade level or higher and to complete study evaluations
- Regular alcohol drinker
Exclusion Criteria:
- Individuals who are seeking alcohol treatment
- Medical conditions that would contraindicate the use of memantine
- Regular use of other substances
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 3
|
Placebo once per day for 7 days
|
Experimental: 1
20 mg memantine
|
Memantine 20 mg once per day for 7 days
Other Names:
|
Experimental: 2
40 mg memantine
|
Memantine 40 mg once per day for 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Drinks Consumed on Day 7
Time Frame: Day 7
|
Day 7
|
|
Baseline-adjusted Craving (YCS)
Time Frame: Day 7
|
Craving for alcohol based on Yale Craving Scale, scores ranging from 0-112 mm on a visual analog scale, with higher measurements indicating higher craving.
The baseline-adjusted craving is change score from baseline at Day 7.
|
Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stimulation Responses to Alcohol
Time Frame: Day 7
|
Brief Biphasic Alcohol Effects Scale-Stimulation subscale, measuring stimulation effects of alcohol on Day 7, 6 items, 11-point rating scale from 0=Not at All to 10=Extremely, total scores ranging from 0 - 30, with higher measurements indicating higher stimulation.
|
Day 7
|
Sedation Responses to Alcohol
Time Frame: Day 7
|
Brief Biphasic Alcohol Effects Scale-Sedation subscale, measuring sedation effects of alcohol on Day 7, 6 items, 11-point rating scale from 0=Not at All to 10=Extremely, total scores ranging from 0 - 30, with higher measurements indicating higher sedation.
|
Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Suchitra Krishnan-Sarin, Ph.D., Yale School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
February 27, 2008
First Submitted That Met QC Criteria
February 27, 2008
First Posted (Estimate)
March 7, 2008
Study Record Updates
Last Update Posted (Actual)
March 17, 2020
Last Update Submitted That Met QC Criteria
March 5, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0602001068
- P50AA012870 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Drinking
-
University of North Carolina, Chapel HillNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingDrinking Behavior | Adolescent Behavior | Drinking, Alcohol | Alcohol Drinking, AdolescentUnited States
-
University of Auckland, New ZealandTe Hiringa Hauora/Health Promotion AgencyCompletedDrinking, Alcohol | Consumption, AlcoholNew Zealand
-
Boston University Charles River CampusRecruiting
-
University of ArkansasRecruitingDrinking Behavior | Drinking Excessive | DrinkingUnited States
-
Butler HospitalNational Institute of General Medical Sciences (NIGMS)CompletedDrinking, AlcoholUnited States
-
Real Prevention, LLCCompletedUnderage Drinking | Alcohol Use, UnderageUnited States
-
Universidad de GranadaCompletedExercise | Drinking, AlcoholSpain
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Active, not recruiting
-
University of North Texas Health Science CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of MinnesotaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Michigan and other collaboratorsCompleted
Clinical Trials on memantine
-
Lyndra Inc.TerminatedHealthy | Gastric RetentionUnited Kingdom
-
Chong Kun Dang PharmaceuticalCompletedAlzheimer's Disease (AD)Korea, Republic of
-
HaEmek Medical Center, IsraelUnknown
-
Merz Pharmaceuticals GmbHLLC Merz Pharma, RussiaCompleted
-
Tianjin Medical University Second HospitalRecruiting
-
GeropharmCompletedBioequivalence, AUC, Cmax, PharmacokineticsRussian Federation
-
H. Lundbeck A/SCompletedAlzheimer Dementia (AD)China
-
University of UtahActive, not recruiting
-
University of Kansas Medical CenterUniversity of Missouri-ColumbiaCompletedAmyotrophic Lateral Sclerosis | Frontal Temporal DementiaUnited States
-
Kenneth Myers, MDCompleted